ASO Author Reflections: Risk-Adapted Use of Adjuvant Systemic Therapy in Real-World Kidney Cancer Care
Year: 2026
Type: article
Abstract: decision-making, and AST should be offered selectively rather than administered universally. FutureFuture studies should evaluate treatment patterns and realworld oncological outcomes as more mature follow-up in the era of adjuvant immune checkpoint inhibition becomes available.Data sources that distinguish between specific systemic agents and capture recurrence, comorbidity, contraindications, and patient preferences will be required to better assess treatment allocation and effectiveness.In parallel, greater awareness of guideline recommendations among treating physicians and multidisciplinary decision-making may help optimize the risk-adapted use of AST in routine clinical practice.
Source: Annals of Surgical Oncology
Institutions: Goethe University Frankfurt, University Hospital Frankfurt, Université de Montréal, University of Milan, IRCCS Policlinico San Donato, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Al-Ahliyya Amman University, Comprehensive Cancer Center Vienna, Weill Cornell Medicine, Medical University of Vienna, The University of Texas Southwestern Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,590
OpenAlex ID: W7204547972